General Cardiology
Hypertrophic cardiomyopathy
HCM management, screening, and emerging therapies
Emerging pathwayAlso known as: HCM, HOCM, hypertrophic obstructive cardiomyopathy
183
Clinical questions
7
Evidence-backed
10
Claims analyzed
General Cardiology
HCM management, screening, and emerging therapies
Emerging evidence with 10 primary claims
First-in-human study of TN-201, an AAV9 gene replacement therapy in <i>MYBPC3</i> -associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1
Cardiovascular Research — Desai M — Nov 2025
Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population
JAMA Cardiology — Lorenzini M — Nov 2019
Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
Journal of the American Heart Association — May 2022
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Circulation — Desai M — Nov 2024
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
Open Heart — Aman A — Feb 2025
Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy
European Heart Journal — Hayashi T — Feb 2000
Clinico-Pathological Evaluation of Restrictive Cardiomyopathy (Endomyocardial Fibrosis and Idiopathic Restrictive Cardiomyopathy) in India
European Journal of Heart Failure — Seth S — Oct 2004
General anxiety, depression, and physical health in relation to symptoms of heart-focused anxiety- a cross sectional study among patients living with the risk of serious arrhythmias and sudden cardiac death
Health and Quality of Life Outcomes — Hamang A — Jan 2011
Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy
EP Europace — Finocchiaro G — Jan 2020
Rapid Device‐Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy
Pacing and Clinical Electrophysiology — Viswanathan K — Mar 2016
The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast‐enhanced magnetic resonance study
Journal of Cardiovascular Electrophysiology — Weissler‐Snir A — Jan 2019
Identifying Ventricular Arrhythmias and Their Predictors by Applying Machine Learning Methods to Electronic Health Records in Patients With Hypertrophic Cardiomyopathy (HCM-VAr-Risk Model)
The American Journal of Cardiology — Bhattacharya M — Feb 2019
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Hypertrophic cardiomyopathy (also known as HCM, HOCM, hypertrophic obstructive cardiomyopathy). HCM management, screening, and emerging therapies
As of 2026-08-14, the scientific consensus on Hypertrophic cardiomyopathy is emerging. Emerging evidence with 10 primary claims Based on 10 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hypertrophic-cardiomyopathy.
Deterministic synthesis from Synapse's enriched corpus — 56 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Hypertrophic cardiomyopathy paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Hypertrophic cardiomyopathy papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers